| Autor: |
van der Wijk AE; Deparment of Biomedical Engineering and Physics, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.; Neurovascular Disorders Program, Amsterdam Neuroscience, The Netherlands.; Microcirculation Program, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands., Georgakopoulou T; Deparment of Biomedical Engineering and Physics, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.; Neurovascular Disorders Program, Amsterdam Neuroscience, The Netherlands.; Microcirculation Program, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands., Steendam R; InnoCore Pharmaceuticals, Groningen, The Netherlands., Zuidema J; InnoCore Pharmaceuticals, Groningen, The Netherlands., Hordijk PL; Neurovascular Disorders Program, Amsterdam Neuroscience, The Netherlands.; Microcirculation Program, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.; Deparment of Physiology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Bakker ENTP; Deparment of Biomedical Engineering and Physics, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.; Neurovascular Disorders Program, Amsterdam Neuroscience, The Netherlands.; Microcirculation Program, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands., van Bavel E; Deparment of Biomedical Engineering and Physics, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.; Neurovascular Disorders Program, Amsterdam Neuroscience, The Netherlands.; Microcirculation Program, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. |
| Abstrakt: |
Drug development for neurological diseases is greatly impeded by the presence of the blood-brain barrier (BBB). We and others previously reported on extravasation of micrometer-sized particles from the cerebral microcirculation - across the BBB - into the brain tissue over the course of several weeks. This mechanism could potentially be used for sustained parenchymal drug delivery after extravasation of biodegradable microspheres. As a first step toward this goal, we set out to evaluate the extravasation potential in the rat brain of three classes of biodegradable microspheres with drug-carrying potential, having a median diameter of 13 µm (80% within 8-18 µm) and polyethylene glycol concentrations of 0%, 24% and 36%. Extravasation, capillary recanalization and tissue damage were determined in a rat cerebral microembolization model at day 14 after microsphere injection. Microspheres of all three classes had the potential to extravasate from the vessel into the brain parenchyma, with microspheres without polyethylene glycol extravasating the fastest. Microembolization with biodegradable microspheres led to impaired local capillary perfusion, which was substantially restored after bead extravasation. We did not observe overt tissue damage after microembolization with any microsphere: we found very limited BBB disruption (IgG extravasation), no microgliosis (Iba1 staining) and no large neuronal infarctions (NeuN staining). In conclusion, biodegradable microspheres with different polymer compositions can extravasate into the brain parenchyma while causing minimal tissue damage. |
